Medical Use
- Aliqopa, a kinase inhibitor, is prescribed for adult patients with relapsed follicular lymphoma (FL) who have undergone at least two prior systemic treatments.
- Recommended Dosage: The suggested dose of Aliqopa is 60 mg, administered as a 60-minute intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle, following an intermittent schedule (3 weeks on, 1 week off). Treatment with Aliqopa should continue until the disease progresses or unacceptable toxicity arises.
-
Warning & Precautions
Severe, including fatal, infections have been reported in patients treated with Copanlisib monotherapy. Patients should be monitored for signs and symptoms of infection, and Copanlisib 60 mg injection should be withheld for Grade 3 or higher infections.
Severe pneumocystis jiroveci pneumonia (PJP) can occur in patients receiving Aliqopa monotherapy. Consider PJP prophylaxis for at-risk individuals before starting treatment.
Grade 3/4 hyperglycemia (blood glucose 250 mg/dL or higher) and severe hyperglycemic events may occur with Aliqopa monotherapy. Ensure optimal blood glucose control before each infusion. Depending on the severity and persistence of hyperglycemia, withhold, reduce the dose, or discontinue therapy.
Grade 3 hypertension (systolic 160 mmHg or higher or diastolic 100 mmHg or higher) has been observed in patients treated with Aliqopa monotherapy. Blood pressure should be monitored before and after infusions. Adjust the dose or interrupt treatment based on the severity and persistence of hypertension.
Non-infectious pneumonitis has been reported in patients treated with Copanlisib monotherapy. If a patient experiences pulmonary symptoms such as dyspnea, cough, hypoxia, or interstitial infiltrates on radiologic exams, withhold the drug and conduct a diagnostic evaluation.
Grade 3/4 neutropenia may occur in patients treated with Aliqopa 60 mg injection. Severe neutropenic events are possible. Blood counts should be monitored at least weekly during therapy. Adjust the dose or interrupt treatment based on the severity and persistence of neutropenia.
This medication can cause fetal harm based on animal studies and its mechanism of action. Women of reproductive age and men with partners of reproductive age should use effective contraception during therapy and for at least 30 days after the final dose.
Documentation Availability
Documents required to import ALIQOPA to India?
ALIQOPA (copanlisib) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing ALIQOPA (Cancer Treatment Medicines) around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Aliqopa®?
The generic name for Aliqopa® is Copanlisib.
Who manufactures Aliqopa®?
Aliqopa® is manufactured by Bayer HealthCare Pharmaceuticals Inc.
Is Aliqopa® FDA approved?
Yes, Aliqopa® was approved by the FDA on September 14, 2017.
What is the dosage and form of Aliqopa®?
Aliqopa® is available as a 60 mg lyophilized solid in a single-dose vial for reconstitution and intravenous administration.
What are the most common side effects of Aliqopa®?
Common side effects include lower respiratory tract infections, hyperglycemia, hypertension, diarrhea, decreased general strength and energy, nausea, leukopenia, neutropenia, and thrombocytopenia.
Can I take Aliqopa if I’m pregnant or breastfeeding?
You must have a negative pregnancy test before starting Aliqopa. Avoid breastfeeding while using this medication and for at least 30 days after the final dose.
How much does Aliqopa® cost in India?
The cost of Aliqopa® in India can vary. For authentic procurement, you can reach out to Rx4u team.
What are the storage conditions for Aliqopa®?
Aliqopa® vials should be refrigerated at 2°C to 8°C (36°F to 46°F).
How to order Aliqopa® online in India?
Aliqopa® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
